NEWS
Pancreatic Cancer Report Urges Changes in Clinical Trials
The slow but steady march toward more individualized care in cancer medicine has left pancreatic cancer behind. Patients diagnosed with this disease live no longer today than patients diagnosed 2 decades ago, despite more than a dozen large clinical trials. Even as many patients with other cancers have benefited from targeted drugs like imatinib (Gleevec) and trastuzumab (Herceptin), pancreatic cancer remains as deadly as ever. Read more > >
Even With Very Small Breast Tumors, Studies Find HER2 Status Matters
Still no clear evidence on whether such tumors should be treated with targeted therapyRisk of Contralateral Breast Cancer Estimated for BRCA Families
Younger age at first diagnosis and BRCA1 gene mutations were risk factorsLower Total Blood Cholesterol Levels Are Not Linked to Higher Cancer Risk
High HDL cholesterol levels may, however, indicate lower riskTests for Catching Cervical Precancers Show Equivalent Accuracy
Large trial indicates either test is an acceptable option for screening programsNicotine Patch and Lozenge Combination Helps Smokers Quit for Longer
Several cessation regimens were compared in a randomized trialPersonalized Phone Counseling Helps Teens Quit Smoking
First trial to show a prolonged effect in this difficult-to-reach population
COMMENTARY
Guest Director's Update: Entering a New Era in Tobacco Control Research
by Dr. Cathy Backinger
With the enactment of the Family Smoking Prevention and Tobacco Control Act on June 22, the United States entered a new era in tobacco control and prevention. While the importance of the new law cannot be overstated, it is only one component of a much larger, comprehensive tobacco control and prevention agenda, for which NCI-supported science is critically important. This issue of the NCI Cancer Bulletin highlights several important tobacco control research studies supported by NCI.
| Subscribe Now! |
IN DEPTH
How Gene Fusions May Occur in Prostate Cancer
Androgens may set the stage for gene rearrangements
Profiles in Cancer Research: Dr. Marcia R. Cruz-Correa
This gastroenterologist and researcher from Puerto Rico is using epigenetics to tackle colorectal cancer
Featured Clinical Trial: Combining Chemotherapy and a PARP Inhibitor for Advanced Solid Tumors
Can a PARP inhibitor safely be added to chemotherapy in patients with solid tumors?
Local Partners Study Mobile Support for DC Tobacco Quitline
Will Internet-based mobile phone technology improve cessation rates?
UPDATES
Cancer.gov Update
- Adolescent and Young Adult Cancer Portal Launched
- A New Face for Smokefree.gov
Notes
- NCI Launches Physical Sciences-Oncology Centers
- Spanish Clinical Trials Promotional Tools Available from NCI
- Meet NCI Experts at APHA
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
